Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

F 14512

Drug Profile

F 14512

Alternative Names: 14512; F14512

Latest Information Update: 13 Mar 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pierre Fabre
  • Class Acetamides; Antineoplastics; Heterocyclic compounds with 4 or more rings
  • Mechanism of Action Apoprotein stimulants; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia

Most Recent Events

  • 13 Mar 2019 Discontinued - Phase-I/II for Acute myeloid leukaemia (Combination therapy, In the elderly, In adults) in Italy, France, Spain (IV)
  • 13 Mar 2019 No development reported - Phase-I/II for Acute myeloid leukaemia (Combination therapy, In the elderly, In adults) in Spain (IV)
  • 15 Feb 2018 Pierre Fabre discontinued a phase-I/II clinical trial in Acute myeloid leukaemia (Combination therapy, In the elderly) in Spain and France (IV) (EudraCT2012-005241-20)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top